Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771894 | 0.93 | LMNA (0.44) | HTR3ACCR2CCR3LMNA | |
| SCHEMBL771768 | 0.90 | CCR3 (0.47) | HTR3ACCR3KMT2ALMNA | |
| SCHEMBL770222 | 0.83 | MEN1 (0.46) | CCR3KMT2ANPSR1 | |
| SCHEMBL771263 | 0.81 | EPHX1 (0.39) | KMT2AMAPK1 | |
| SCHEMBL771584 | 0.80 | ALDH1A1 (0.47) | KMT2ALMNAMAPT | |
| SCHEMBL771349 | 0.80 | CACNA1H (0.37) | KCNH2MAPTSMN1; SMN2 | |
| SCHEMBL770654 | 0.80 | EPHX1 (0.50) | SMN1; SMN2 | |
| SCHEMBL770322 | 0.80 | EPHX1 (0.50) | SMN1; SMN2 | |
| SCHEMBL771634 | 0.79 | KEAP1 (0.48) | CCR3LMNA | |
| SCHEMBL770945 | 0.79 | NAAA (0.36) | KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HTR3A 1502/4885CCR2 3149/4885CCR3 3880/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HTR3A 1501/4885CCR2 3168/4885CCR3 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.